Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

IVERIC Bio Inc (ISEE) Ordinary Shares

Sell:$6.02 Buy:$6.06 Change: $0.16 (2.55%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
Change: $0.16 (2.55%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
Change: $0.16 (2.55%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovering and developing of treatment options for retinal diseases. The Company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases (IRDs). The Company’s therapeutics portfolio consists of its clinical stage product candidate Zimura (avacincaptad pegol), a complement C5 inhibitor, and IC-500, its preclinical product candidate from its High temperature requirement A serine peptidase one protein (HtrA1), inhibitors program. Its lead gene therapy products also includes IC-100 and IC-200.

Contact details

5 Penn Plaza, Suite 2372
United States
+1 (212) 8458200

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$539.20 million
Shares in issue:
90.14 million
United States
US dollar

Key personnel

  • David Guyer
    Executive Chairman of the Board
  • Glenn Sblendorio
    President, Chief Executive Officer, Director
  • David Carroll
    Chief Financial Officer, Senior Vice President, Treasurer
  • Keith Westby
    Chief Operating Officer, Senior Vice President
  • Pravin Dugel
    Executive Vice President, Chief Strategy and Business Officer
  • Abraham Scaria
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.